Association of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection

Table 3 Genetic models of association between interferon lambda-4 rs12979860 polymorphism and hepatitis C virus-associated liver diseases

rs12979860	Fibrosis vs Control		Cirrhosis vs Control		HCC vs Control		Fibrosis vs Cirrhosis		Cirrhosis vs HCC
	OR (95%CI)	P value	OR (95%CI)	P value	OR (95%CI)	P value	OR (95%CI)	P value	OR (95%CI)	P value
Codominant model
CC	1.00 (Ref.)	-	1.00 (Ref.)	-	1.00 (Ref.)	-	1.00 (Ref.)	-	1.00 (Ref.)	-
CT	1.69 (0.82-3.54)	0.126	2.53 (1.55-4.15)	< 0.001	2.54 (1.44-4.56)	0.001	1.50 (0.67-3.28)	0.277	1.01 (0.52-1.95)	0.986
TT	2.40 (0.87-6.27)	0.053	2.88 (1.44-5.77)	0.001	2.08 (0.86-4.83)	0.068	1.20 (0.43-3.45)	0.702	0.72 (0.28-1.80)	0.447
T allele dominant model
CC	1.00 (Ref.)	-	1.00 (Ref.)	-	1.00 (Ref.)	-	1.00 (Ref.)	-	1.00 (Ref.)	-
CT + TT	1.83 (0.94-3.71)	0.061	2.60 (1.63-4.19)	< 0.001	2.45 (1.42-4.31)	0.001	1.42 (0.66-2.97)	0.325	0.94 (0.50-1.79)	0.840

CI: Confidence interval; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; OR: Odds ratio; Ref.: Reference.